Trial · NCT04294901
Engaging Patients to Promote Deprescribing
NCT04294901, Not applicable, Completed, VA Office of Research and Development; results first posted 2025-05-18
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Engaging Patients to Promote Deprescribing. Trials, record NCT04294901. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04294901
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Engaging Patients to Promote Deprescribing
- NCT number
- NCT04294901
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 5,946 participants, actual
- Lead sponsor
- VA Office of Research and Development
- Conditions
- Medical Overuse, Inappropriate Prescribing, Deprescriptions
- Interventions
- Direct to patient medication brochure
- First posted
- 2020-03-04
- Last updated
- 2025-05-18
- Results first posted
- 2025-05-18
- Limitations and caveats
- Total numbers for Baseline Characteristics are less than the number of subjects due to missing data
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Deprescribing | 6 months post-index date | Non-refill of the medication in the 6 months following the primary care appointment (i.e., cessation) or any reduction in the total daily dose (i.e., de-escalation). There is an exception to the de-escalation rule for insulin, where only complete cessation will qualify since dose changes are less likely to be reflected in the order compared to oral medications. |
| Secondary | Deprescribing Conversations | Index visit until survey completion (up to 8 weeks post-index visit) | Patient report of a conversation about deprescribing during the index primary care visit. Note that this Outcome Measure was only assessed in a subsample of the "Intervention Group" Arm/Group participants and not at all in the "Historical Control Group" Arm/Group subjects. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Deprescribing | 6 months post-index date | It is pre-specified in the Study Protocol and Statistical Analysis Plan to assess all medication groups combined within the Intervention and Control Arms/Groups | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Deprescribing Conversations | Index visit until survey completion (up to 8 weeks post-index visit) | Note that this Outcome Measure was only assessed in a subsample of the Intervention Group Arm/Group participants who responded to the survey. It was not assessed at all in the Historical Control Group Arm/Group subjects. | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group5
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Deprescribing | Intervention Group | 748 | Participants | ||
| Deprescribing | Historical Control Group | 653 | Participants | ||
| Deprescribing Conversations | Gabapentin (Gaba) | 12 | Participants | ||
| Deprescribing Conversations | Diabetes (DM) | 37 | Participants | ||
| Deprescribing Conversations | Proton Pump Inhibitor (PPI) | 353 | Participants |
Source ClinicalTrials.gov
Participant flow12
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Intervention Group | 3,206 | |
| Overall Study | STARTED | Historical Control Group | 2,740 | |
| Overall Study | PPI | Intervention Group | 2,064 | |
| Overall Study | PPI | Historical Control Group | 2,000 | |
| Overall Study | DM-Hypoglycemia Risk | Intervention Group | 378 | |
| Overall Study | DM-Hypoglycemia Risk | Historical Control Group | 427 | |
| Overall Study | Gabapentin | Intervention Group | 97 | |
| Overall Study | Gabapentin | Historical Control Group | 105 | |
| Overall Study | COMPLETED | Intervention Group | 2,539 | |
| Overall Study | COMPLETED | Historical Control Group | 2,532 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 participant flowAdverse events2
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Potential adverse drug withdrawal event | General disorders | Intervention Group | 25 | 2,539 | 25 |
| serious | Potential adverse drug withdrawal event | General disorders | Historical Control Group | 26 | 2,532 | 26 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Intervention Group | 86 | 3,206 |
| Total, all-cause mortality | Historical Control Group | 110 | 2,740 |
| Total, other adverse events | Intervention Group | 0 | 2,539 |
| Total, other adverse events | Historical Control Group | 0 | 2,532 |
| Total, serious adverse events | Intervention Group | 25 | 2,539 |
| Total, serious adverse events | Historical Control Group | 26 | 2,532 |
Source ClinicalTrials.gov
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons3
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Intervention Group vs Historical Control Group: Deprescribing | Trial comparisons |
| Intervention Group vs Historical Control Group: deaths from any cause | Trial comparisons |
| Intervention Group vs Historical Control Group: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04294901
GET https://conductscience.org/api/trials/v1/NCT04294901/registered